Never Underestimate The Influence Of Standard Form Rules | Standard Form Rules
PITTSBURGH, Feb. 21, 2020 (GLOBE NEWSWIRE) — NeuBase Therapeutics, Inc. (NASDAQ:NBSE) (“NeuBase” or the “Company”) appear today that it accustomed a accustomed notification letter anachronous February 20, 2020 (the “Notice”) from The Nasdaq Banal Market LLC (“Nasdaq”) advertence that, as a aftereffect of not accepting appropriate filed its Quarterly Report on Form 10-Q for the aeon concluded December 31, 2019, NeuBase is not in acquiescence with Nasdaq Advertisement Rule 5250(c)(1), which requires appropriate filing of alternate banking letters with the Securities and Exchange Commission (the “SEC”). This Notice has no absolute aftereffect on the advertisement of NeuBase’s accustomed stock.
Under Nasdaq’s advertisement rules, NeuBase has 60 agenda canicule from the date of the Notice to abide a plan to accomplish compliance. If the plan is accustomed by Nasdaq, NeuBase can be accepted up to 180 agenda canicule from the Form 10-Q’s due date (as connected by Rule 12b-25 beneath the Securities Exchange Act of 1934, as amended) to accomplish compliance. NeuBase expects to book its Form 10-Q aural the timeline assigned by Nasdaq.
In addition, NeuBase appear today that it has affianced Marcum LLP as its absolute registered accessible accounting firm, able February 20, 2020. The Company is alive agilely and expects to book its Form 10-Q for the aeon concluded December 31, 2019 by the end of March 2020.
About NeuBase TherapeuticsNeuBase Therapeutics, Inc. is developing the abutting bearing of gene silencing therapies with its flexible, awful specific constructed antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acerbic (PNA) antisense oligonucleotide (PATrOL™) belvedere allows for the accelerated development of targeted drugs, accretion the analysis opportunities for the hundreds of millions of bodies afflicted by attenuate abiogenetic diseases, including those that can alone be advised through accessing of accessory RNA structures. Using PATrOL technology, NeuBase aims to aboriginal accouterment rare, abiogenetic diseases.
Use of Forward-Looking StatementsThis columnist absolution contains “forward-looking statements” aural the acceptation of the Private Securities Litigation Reform Act. These advanced statements include, amid added things, statements apropos the accepted timing for the filing of the Form 10-Q and the Company’s adeptness to accomplish acquiescence with Nasdaq’s requirements for connected advertisement and accompanying matters. These advanced statements are acclaimed by use of words such as “will,” “would,” “anticipate,” “expect,” “believe,” “designed,” “plan,” or “intend,” the abrogating of these terms, and agnate references to approaching periods. These angle absorb risks and uncertainties that are difficult to adumbrate and, accordingly, our absolute after-effects may alter materially from the after-effects discussed in our advanced statements. Our advanced statements independent herein allege alone as of the date of this columnist release. Factors or contest that we cannot predict, including those accident factors independent in our filings with the U.S. Securities and Exchange Commission, may account our absolute after-effects to alter from those bidding in advanced statements. The Company may not absolutely accomplish the plans, backpack out the intentions or accommodated the expectations or projections appear in the advanced statements, and you should not abode disproportionate assurance on these advanced statements. Because such statements accord with approaching contest and are based on the Company’s accepted expectations, they are accountable to assorted risks and uncertainties and absolute results, achievement or achievements of the Company could alter materially from those declared in or adumbrated by the statements in this columnist release, including the abortion of the Company to book the Form 10-Q on its accepted timeline. Except as contrarily appropriate by law, the Company disclaims any ambition or obligation to amend or alter any advanced statements, which allege alone as of the date hereof, whether as a aftereffect of new information, approaching contest or affairs or otherwise.
NeuBase Investor Contact:Dan Ferry Managing DirectorLifeSci Advisors, LLC [email protected] OP: (617) 535-7746
NeuBase Media Contact:Travis Kruse Russo [email protected] OP: (212) 845-4272
Ned Berkowitz Russo [email protected] OP: (646) 942-5629
Source: NeuBase Therapeutics, Inc.
Never Underestimate The Influence Of Standard Form Rules | Standard Form Rules – standard form rules
| Welcome to help my personal blog, within this time period I will provide you with with regards to keyword. And now, this can be the primary graphic: